Medicine and Dentistry
Gut
100%
Glucagon Like Peptide 1
100%
Glycemic Control
100%
Glucagon Like Peptide 2
100%
Body Weight
80%
Monotherapy
60%
Chronic Drug Administration
60%
Maturity Onset Diabetes of the Young
40%
Short Bowel Syndrome
40%
Stomach Emptying
40%
Glucose Tolerance
40%
Food Intake
40%
Glucose Homeostasis
20%
Pharmacokinetic
20%
Small Intestine
20%
Peptide Synthesis
20%
Liraglutide
20%
Gastrointestinal Polypeptide
20%
Diseases
20%
Medicine
20%
Mucosal Surface
20%
Diabetes Mellitus
20%
Morphometrics
20%
Teduglutide
20%
Peptide Hormone
20%
Keyphrases
Glucagon-like
100%
Glycemic Control
100%
Co-agonist
100%
Leaner Mouse
30%
Monotherapy
30%
Type 2 Diabetes Mellitus (T2DM)
20%
Short Bowel Syndrome
20%
Glucose Tolerance
20%
Gastric Emptying
20%
Short-acting
20%
Diabetic
10%
Diabetic Mice
10%
Disease Treatment
10%
Solid-phase Peptide Synthesis
10%
Glucose Homeostasis
10%
Liraglutide
10%
Persistent Effects
10%
Food Intake
10%
Type 2 Diabetes Prevention
10%
Obesity
10%
Db Mouse
10%
Mucosal Surfaces
10%
Gastrointestinal Hormones
10%
Long-term Glycaemic Control
10%
Teduglutide
10%
Reduced Food Intake
10%
Agonistic
10%
Small Intestine
10%
Pharmacokinetic Properties
10%
Dose Effect
10%
Chronic Administration
10%
Pharmacology, Toxicology and Pharmaceutical Science
Glucagon Like Peptide 2
100%
Glucagon-Like Peptide-1
100%
Leaner Mutant Mouse
60%
Monotherapy
60%
Short Bowel Syndrome
40%
Non Insulin Dependent Diabetes Mellitus
40%
Db/Db Mouse
20%
Teduglutide
20%
Liraglutide
20%
Diseases
20%
Pharmacokinetic
20%
Peptide Hormone
20%
Gastrointestinal Polypeptide
20%
Diabetes Mellitus
20%